Japanese hypertensive patients with CKD.
Conditions
Interventions
This study is a prospective randomized control trial. The entry period of this study is two years. Study subjects are hypertensive patients with CKD, taking RAS inhibitors (ACEI and/or ARB). These pat
Sponsors
Graduate School of Medicine, Tohoku University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The subjects enrolled in the present study are hypertensive out-patients with CKD, who fulfill the following criteria; 1) Mild or moderate hypertension defined as the blood pressure of 130 / 90 – 160 / 110 mmHg. 2) Taking of RAS inhibitors such as ACEI and/or ARB, for at least six months. 3) Corresponding to the second stage – the fourth stage of CKD (eGFR=15-89 ml/min). 4) The participation agreement of this study is obtained.
Exclusion criteria
Exclusion criteria: 1) Corresponding to the CKD 5th stage (eGFR < 15 ml/min, or receiving continuous dialysis). 2) Woman who has pregnancy or possibility of pregnancy and suckling. 3) To have other serious and active diseases such as severe hyperglycemia (HbA1c > 10%), liver dysfunction, cardiovascular disease and so on). 4) Severe hypertensive subjects (> 160 / 110 mmHg). 5) The patient that corresponds to contraindication of Aliskiren treatment. 6) Patient from whom physician in charge of treatment judged this study participation to be improper.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percent change of eGFR | — |
Secondary
| Measure | Time frame |
|---|---|
| Percent changes of the urinary albumin, MCP-1, 8-OHdG, NAG and beta2-microgloburin excretions. | — |
Countries
Japan
Contacts
Public ContactSusumu Ogawa
Tohoku University Hospital Division of Nephrology, Endocrinology and Hypertension
Outcome results
None listed